ペプチド治療薬の世界市場:ソマトスタチン、バソプレシン、カルシトニン、LHRH、グルカゴン、インシュリン...市場調査レポートについてご紹介

【英文タイトル】Global Peptide Therapeutics Market 2016-2020

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

PART 01: Executive summary
• Highlights

PART 02: Scope of the report
• Market overview
• Top-vendor offerings

PART 03: Market research methodology
• Research methodology
• Economic indicators

PART 04: Introduction
• Key market highlights

PART 05: Overview of peptides
• Peptide synthesis
• Optimization of peptides
• Stabilization of peptides

PART 06: Market landscape
• Market overview
• Market size and forecast
• Five forces analysis

PART 07: Market segmentation based on route of administration
• Parenteral
• Oral
• Pulmonary
• Mucosal

PART 08: Market segmentation by drug class
• Somatostatins
• Vasopressin
• Calcitonins
• Luteinizing hormone (LH)-releasing hormone (LHRH)
• Glucagon and analogs
• Insulins
• Other

PART 09: Market segmentation by synthesis technology
• Liquid-phase peptide synthesis
• Solid-phase peptide synthesis
• Hybrid peptide synthesis

PART 10: Geographical segmentation
• Global peptide therapeutics market segmentation by geography 2015-2020
• Peptide therapeutics market in Americas
• Peptide therapeutics market in EMEA
• Peptide therapeutics market in APAC

PART 11: Market drivers
• Increase in patient population
• Advances in peptide synthesis technology
• Promising pipeline
• Unmet medical needs
• Increase in healthcare spending

PART 12: Impact of drivers

PART 13: Market challenges
• High cost of therapy
• Adverse side effects
• Stringent regulatory compliances
• Intense market competition

PART 14: Impact of drivers and challenges

PART 15: Market trends
• Growing popularity
• Shifting focus toward untapped markets
• Contract manufacturing
• Increase in public awareness

PART 16: Vendor landscape
• Competitive scenario
• Eli Lilly
• Novo Nordisk
• Sanofi
• Takeda Pharmaceutical
• Teva Pharmaceuticals
• Other prominent vendors

PART 17: Appendix
• List of abbreviations

PART 18: Explore Technavio

[List of Exhibits]

Exhibit 01: Product offerings
Exhibit 02: SWOT analysis: Peptide therapeutics
Exhibit 03: Steps involved in peptide synthesis
Exhibit 04: Optimization of peptide synthesis
Exhibit 05: Methods used to stabilize peptides
Exhibit 06: Global peptide therapeutics market 2015-2020 ($ billions)
Exhibit 07: Five forces analysis
Exhibit 08: Global peptide therapeutics market segmentation based on route of administration
Exhibit 09: Global peptide therapeutics market segmentation by route of administration 2015
Exhibit 10: Global peptide therapeutics market segmentation by drug class
Exhibit 11: Global peptide therapeutics market segmentation by synthesis technology
Exhibit 12: Global peptide therapeutics market segmentation by geography 2015
Exhibit 13: Peptide therapeutics market revenue by geography 2015-2020 ($ billions)
Exhibit 14: Peptide therapeutics market in Americas 2015-2020 ($ billions)
Exhibit 15: Peptide therapeutics market in EMEA 2015-2020 ($ billions)
Exhibit 16: Peptide therapeutics market in APAC 2015-2020 ($ billions)
Exhibit 17: Global peptide therapeutics market: YoY growth and revenue based on geography 2015-2020
Exhibit 18: Impact of drivers
Exhibit 19: Impact of drivers and challenges
Exhibit 20: El Lilly: YoY growth rate and revenue of Humalog 2012-2014 ($ billions)
Exhibit 21: Eli Lilly: YoY growth rate and revenue of Cialis 2012-2014 ($ billions)
Exhibit 22: Eli Lilly: YoY growth rate and revenue of Cymbalta 2012-2014 ($ billions)
Exhibit 23: Eli Lilly: YoY growth rate and revenue of Humulin 2012-2014 ($ billions)
Exhibit 24: Eli Lilly: YoY growth rate and revenue of Forteo 2012-2014 ($ billions)
Exhibit 25: Eli Lilly: Key takeaways
Exhibit 26: Novo Nordisk: YoY growth rate and revenue of NovoLog/NovoRapid 2012-2014 ($ billions)
Exhibit 27: Novo Nordisk: Geographical split of revenues of NovoLog 2014
Exhibit 28: Novo Nordisk: YoY growth rate and revenue of NovoMix/NovoLog mix 2012-2014 ($ billions)
Exhibit 29: Novo Nordisk: Geographical split of revenues of NovoMix 2014
Exhibit 30: Novo Nordisk: YoY growth rate and revenue of Norditropin 2012-2014 ($ billions)
Exhibit 31: Novo Nordisk: Geographical split of revenues of Norditropin 2014
Exhibit 32: Novo Nordisk: YoY growth rate and revenue of Prandin 2012-2014 ($ millions)
Exhibit 33: Novo Nordisk: Geographical split of revenues of Prandin 2014
Exhibit 34: Novo Nordisk: Key takeaways
Exhibit 35: Sanofi: YoY growth rates and revenues of Lantus 2012-2014 ($ billions)
Exhibit 36: Sanofi: YoY growth rate and revenue of Amaryl 2012-2014 ($ millions)
Exhibit 37: Sanofi: YoY growth rate and revenue of Apidra 2012-2014 ($ millions)
Exhibit 38: Sanofi: YoY growth rate and of Insuman 2012-2014 ($ millions)
Exhibit 39: Sanofi: YoY revenue of Lyxumia 2013-2014 ($ millions)
Exhibit 40: Sanofi: Key takeaways
Exhibit 41: Takeda Pharmaceutical: YoY revenue of Velcade 2013-2014 ($ billions)
Exhibit 42: Takeda Pharmaceutical: YoY revenue of Leuprorelin 2013-2014 ($ billions)
Exhibit 43: Takeda Pharmaceutical: YoY revenue of Nesina 2013-2014 ($ millions)
Exhibit 44: Takeda Pharmaceutical: YoY revenue of TachoSil 2013-2014 ($ millions)
Exhibit 45: Takeda Pharmaceutical: Key takeaways
Exhibit 46: Teva Pharmaceuticals: YoY growth rate and revenue of Copaxone 2012-2014 ($ billions)
Exhibit 47: Teva Pharmaceuticals: Key takeaways


【レポート販売概要】

■ タイトル:ペプチド治療薬の世界市場:ソマトスタチン、バソプレシン、カルシトニン、LHRH、グルカゴン、インシュリン
■ 英文:Global Peptide Therapeutics Market 2016-2020
■ 発行日:2016年3月4日
■ 調査会社:Technavio
■ 商品コード:IRTNTR8630
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。